SLC5A2 and cancer: These findings are supported by a large real-world meta-analysis of randomized controlled trials involving nearly 30,000 patients treated with SGLT2 inhibitors and nearly the same number of control individuals, which found no statistically significant differences in overall cancer risk between SGLT2 inhibitor users and matched controls [182].